Open for applications

Your Challenge:
Continuous Hormone Monitoring

Hormones control nearly every process in the human body – from metabolism and immune function to cognition and reproduction. Yet how we measure them is static: one moment, one value. Hormones follow highly dynamic patterns however – they fluctuate throughout the day, across the cycle, in response to stress, sleep and nutrition. This dynamic currently remains invisible.

Women are particularly affected. Their hormonal systems show the greatest variability – and have been structurally underrepresented in research for a long time. Even today, diagnoses are based on reference ranges that consider neither cycle phase nor time of day nor individual baseline. Diseases such as endometriosis, PCOS, autoimmune disorders or hormone-dependent cardiovascular diseases are detected too late or not understood at all. AI models are trained on the same incomplete data.

What we need are sensors that measure continuously in everyday life. Sensors that make visible what remains hidden today.

00:00

The challenge: to develop biosensors that continuously measure at least four hormones over seven days – with sufficient temporal resolution to capture biological dynamics without loss of information.

In the Challenge, teams will develop sensor technologies that enable continuous hormone monitoring for the first time. At least four hormones must be captured – including estrogen, progesterone, LH, FSH, cortisol, testosterone or thyroid hormones. The temporal resolution of measurements must be chosen to capture the specific biological dynamics and pulsatility of the selected hormone panel without loss of information. Measurement occurs over at least seven consecutive days, directly in a biological matrix such as interstitial fluid, sweat or saliva.

Each team defines a concrete, transformative use case based on clinical-grade data: Early detection of preeclampsia through longitudinal estrogen profiles? Optimization of hormone-dependent drug dosing across the cycle? Prediction of luteal insufficiency before clinical symptoms emerge? The goal is to develop a platform technology fundamentally capable of making visible highly dynamic processes that remain hidden in current clinical practice due to insufficient data point density. This should create new possibilities for therapy and diagnostics that would not be possible without the developed technology.

In parallel, a shared reference data pool is created – the first standardized collection of continuous hormone data across populations, life phases and health conditions. This pool will form the foundation for precise calibration, further research, and AI-powered precision medicine.

Teams participating in this Challenge are fully challenged. SPRIND therefore provides intensive and individual support. This includes funding the teams with up to €1.5 million in Stage 1, up to €2 million in Stage 2 and up to €2.5 million in the final Stage 3 of the Challenge. In order to help the teams develop their full potential, SPRIND provides them not only with financial support but also with mentors who accompany, advise and network the work of each team.

To enable the teams to concentrate fully on their innovations, we provide funding quickly and unbureaucratically. The first stage starts in July 2026: After one year, the jury decides on the basis of interim evaluations which teams will continue to participate in the Challenge. As finalists, these teams are given the opportunity to drive their project forward for another twelve months. The best teams receive another twelve months in Stage 3 to comprehensively demonstrate their breakthrough.

Thinking one step further: Ideas with the potential for a breakthrough innovation must be brought to market to benefit us all – promising projects in this sense can therefore continue to be supported by SPRIND after the Challenge has ended.

Detailed information can be found in the call for submissions and the participation agreement.

Want to learn more about the Challenge or still have open questions? Register for our webinar on June 1, 2026, at 5:00 PM (CEST). We’ll provide an overview of the program and answer your questions live.

The application period runs until 26 June 2026 (6pm CEST). All applications submitted by this deadline will be considered.

SPRIND supports all teams in achieving the Challenge goal. This includes that SPRIND finances the work of the teams from the beginning of the Challenge. In addition, we provide all teams with mentors who have extensive experience in implementing breakthrough innovations. From this experience, the mentors support the teams, for example, in planning work packages and experiments, or in networking with collaboration partners or subcontractors. In addition, SPRIND uses its network to promote the implementation of breakthrough innovations.

All expenses that serve to achieve the Challenge goal can be financed with SPRIND funds. This can include, for example, personnel costs, equipment and materials or rent.

The intellectual property rights created by the teams during the Challenge remain with the teams. SPRIND receives a free and non-exclusive right to use the results found. Details can be found in the Participation agreement and the IP FAQ.

SPRIND is committed to supporting innovators in implementing breakthrough innovations. If SPRIND identifies breakthrough innovation potential in the teams during the Challenge, their work can continue to be supported after the Challenge has ended.

The application deadline is 26 June 2026 at 6pm CEST.

A team of SPRIND experts makes a preliminary selection from the applications received. The final decision is made by the jury. The final decision on admission to the Challenge is made on the basis of the application and the pitch. The pitch will take place on July 9th and 10th 2026 in Leipzig.

The Challenge has a total duration of 3 years. At the end of the one-year Stage 1 of the Challenge, a further selection round takes place to determine which of the Challenge teams will also be funded by SPRIND in Stage 2.

Applications beginning 11 May 2026 are only possible via the online application form. Applications must be submitted in English only.

All Challenge teams are in close contact with SPRIND and the mentoring team during the course of the Challenge. This ensures a targeted innovation process in which emerging hurdles can be identified and addressed at an early stage. Furthermore, no detailed statements on the use of funding are required.

It is possible to participate in the Challenge for both individual participants as well as teams. Teams in all legal forms such as universities, non-university research institutions, established companies, start-ups and incubators can apply. It is also possible to form teams out of different entities. If the application is not made as a company, a spin-off must be established no later than in Stage 2.

Teams can participate if they are located in either the European Union, the European Free Trade Association, the United Kingdom or in Israel. Individual team members or cooperation partners can be located outside of this region.

In principle, all sensor technologies and biological matrices are eligible –from wearable devices to implantable systems, and from interstitial fluid to sweat, saliva, or blood. However, two requirements are non-negotiable: measurements must be performed continuously and on-site—collecting samples for laboratory analysis is not permitted. In addition, measurements must target the hormone of interest directly. Surrogate markers or indirect parameters such as heart rate or temperature are not accepted as proxies for hormone levels.

Do you have any questions about the Challenge? Write to us at challenge@sprind.org.

Jano Costard, Challenge Officer
Jano Costard, Challenge Officer
Send Email
LinkedIn
Instagram
Youtube
X (Twitter)
Bluesky
Mastodon
Newsletter
When signing up for the SPRIND newsletter, our general privacy statement applies.
SprinD GmbH, Lagerhofstr. 4, 04103 Leipzig, info@sprind.org